- Report
- November 2025
- 150 Pages
Global
From €5331EUR$5,950USD£4,567GBP
- Report
- January 2026
- 199 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- July 2026
- 198 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- July 2026
- 180 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- June 2026
- 186 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- June 2026
- 185 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- June 2026
- 191 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- June 2026
- 192 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- January 2026
- 196 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- January 2026
- 198 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- January 2026
- 193 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- January 2026
- 182 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- January 2026
- 190 Pages
Global
From €3176EUR$3,545USD£2,721GBP
€3529EUR$3,939USD£3,023GBP
- Report
- August 2026
- 575 Pages
Global
From €5242EUR$5,850USD£4,490GBP
- Report
- August 2026
- 462 Pages
Global
From €5242EUR$5,850USD£4,490GBP
- Report
- August 2026
- 380 Pages
Global
From €5242EUR$5,850USD£4,490GBP
- Report
- August 2026
- 188 Pages
Global
From €5242EUR$5,850USD£4,490GBP
- Report
- August 2026
- 183 Pages
Global
From €5242EUR$5,850USD£4,490GBP
- Report
- February 2026
- 250 Pages
Global
From €4023EUR$4,490USD£3,446GBP
- Report
- February 2026
- 250 Pages
Global
From €4023EUR$4,490USD£3,446GBP

Alkylating agents are a class of immunosuppressive drugs used to treat autoimmune diseases, organ transplant rejection, and certain types of cancer. These drugs work by inhibiting the growth of cells, including those of the immune system, and by preventing the formation of new blood vessels. Common alkylating agents include cyclophosphamide, chlorambucil, and melphalan.
Alkylating agents are used in combination with other immunosuppressive drugs to reduce the risk of organ rejection and to treat autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis. They are also used to treat certain types of cancer, such as lymphoma and leukemia.
The alkylating agent market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and GlaxoSmithKline. Other companies include Sanofi, AstraZeneca, and Bayer. Show Less Read more